WCLC Sept 2021 | Technical considerations for ctDNA testing in NSCLC
Maria Arcila, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of her presentation at the World Conference on Lung Cancer (WCLC) 2021 on the key technical considerations for circulating tumor DNA (ctDNA) testing in patients with advances non-small cell lung cancer (NSCLC). In the pre-analytic stages of testing, important considerations include unique patient factors that impact quantity and quality of cell-free DNA (cfDNA) in the circulation, as well as variability in methods for the collection and processing of samples. The analytical processes used to characterize cfDNA and sensitivity of the technology used, as well as how results are interpreted, are other important factors that must be considered. This interview took place at the WCLC 2021.
Disclosures
Maria Arcila has has participated in a consulting or advisory role for Janssen Global Services, Bristol-Myers Squibb & AstraZeneca. She has also received speaker honoraria from Biocartis, Invivoscribe Inc, Physician Educational Resources, PeerView Institute for Medical Education, Clinical Care Options & RMEI Medical Education.
